申请人:KALLYOPE INC
公开号:WO2020242943A1
公开(公告)日:2020-12-03
This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
这份公开信息至少部分涉及用于治疗涉及肠-脑轴的条件或疾病的GPR40激动剂。在某些实施例中,GPR40激动剂是肠道限制性化合物。在某些实施例中,GPR40激动剂是全激动剂或部分激动剂。在某些实施例中,所述条件或疾病是一种代谢紊乱,如糖尿病、肥胖、非酒精性脂肪肝炎(NASH)或一种营养紊乱,如短肠综合征。